Telzuit Medical Technologies, Inc. Signs License Agreement With Philips Electronics For Holter Monitoring Software

ORLANDO, Fla., April 6 /PRNewswire-FirstCall/ -- Telzuit Medical Technologies, Inc. (the "Company" or "Telzuit") announced today that it has signed an agreement with Koninklijke Philips Electronics N.V. , to license its Zymed Holter Monitoring Software as part of the Bio-Patch back office data center. This reporting software will allow the raw patient data from the Bio-Patch to be converted into a comprehensive 12 lead Holter monitor report. This report will then be made available to the physician via a secure web portal or fax. Terms of the agreement were not disclosed.

Warren Stowell, CEO of Telzuit, commented, "Today's announcement is the final step in the development of our remote data center, and with this critical software in place, we are now positioned to penetrate the cardiovascular market with our revolutionary Bio-Patch Wireless Holter Monitor. We are committed to utilizing the most state-of-the-art technology throughout the development of our Bio-Patch System. The implementation of the Zymed Holter Monitoring Software will now allow physicians to view any number of patients' Holter reports remotely through our secure server. We look forward to the full market launch of our Bio-Patch, demonstrating to patients and physicians alike the impressive advances we have made in mobile medical technology."

About Telzuit Medical Technologies, Inc.

Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile medicine for people worldwide. The company is in the final stages of launching its first product, the FDA-approved Bio-Patch Wireless Heart Monitor. The Bio-Patch is a full 12-lead, completely wireless Holter monitor, which is new to the marketplace. In conjunction with its strategic partners, Telzuit is also building its own dedicated intranet platform to handle several of the products it will be releasing, including the Bio-Patch. Telzuit is based in Orlando, Florida. For more information Telzuit, its business model and its products, please visit the company's website: http://www.telzuit.com .

Forward Looking Statement: Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the effect of changing economic conditions, competition within the health products industry, customer acceptance of products, and other risks and uncertainties. Such forward-looking statements are not guarantees of performance, and Telzuit results could differ materially from those contained in such statements. These forward-looking statements speak only as of the date of this release, and Telzuit undertake no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.

Contact: Telzuit Medical Technologies, Inc. James Tolan Co-Founder, Telzuit Medical Technologies, Inc. 407-354-1222 Brainerd Communicators, Inc. Jennifer Gery (media) Todd St.Onge (investors) 212-986-6667

Telzuit Medical Technologies, Inc.

CONTACT: James Tolan, Co-Founder of Telzuit Medical Technologies, Inc.,+1-407-354-1222; or Jennifer Gery (media) or Todd St.Onge (investors),+1-212-986-6667, both of Brainerd Communicators, Inc. for Telzuit MedicalTechnologies, Inc.

Back to news